🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
This is a one-day, randomized, double-masked, single-center evaluation of t...
Status
Completed
Location
Andover Eye Associates
Start Date
2015-09
Trial ID
NCT02554396
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evalu...
Status
Completed
Location
Eye Hospital, Wenzhou Medical University
Start Date
2023-09-27
Trial ID
NCT06045299
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ...
Status
Completed
Location
Site #209
Start Date
2023-03-06
Trial ID
NCT05728944
Treatments Being Tested
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101)...
Status
Completed
Location
INSIGHT-2 Study Site #5
Start Date
2022-08-06
Trial ID
NCT05431543
To evaluate the safety and efficacy of PRX-100 compared with aceclidine alo...
Status
Completed
Location
Andover Eye Associates
Start Date
2017-04-30
Trial ID
NCT03201562
Treatments Being Tested
Phase 3 study to evaluate the safety and effectiveness of LNZ100 \& LNZ101 ...
Status
Completed
Location
Site #106
Start Date
2022-12-19
Trial ID
NCT05656027
Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokin...
Status
Completed
Location
Shanghai General Hospital
Start Date
2024-03-04
Trial ID
NCT06270030
Safety Study of the Long-Term Safety of LNZ100 \& LNZ101 in Presbyopic Subj...
Status
Completed
Location
Site #326
Start Date
2023-02-21
Trial ID
NCT05753189
Treatments Being Tested
This is a single-center, open-label, randomized study to assess the plasma ...
Status
Completed
Location
Site #101
Start Date
2023-07-06
Trial ID
NCT05936489
Treatments Being Tested
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101)...
Status
Completed
Location
INSIGHT-1 Study Site #4
Start Date
2022-05-05
Trial ID
NCT05294328